• pediatric ulcerative colitis;
  • acute severe colitis;
  • PUCAI;
  • corticosteroids;
  • cyclosporine;
  • tacrolimus;
  • infliximab


Pediatric ulcerative colitis (UC) has a more severe phenotype, reflected by more extensive disease and a higher rate of acute severe exacerbations. The pooled steroid-failure rate among 291 children from five studies is 34% (95% confidence interval [CI]: 27%–41%). It is suggested that corticosteroids should be dosed between 1–1.5 mg/kg up to 40–60 mg daily. Food restriction has a limited role in severe UC and should be generally discouraged in children who do not have a surgical abdomen. Appraisal of radiologic findings in children must recognize the variation in colonic width with age and size. Data suggest that the Pediatric UC Activity Index (PUCAI), determined at day 3, should be used to screen for patients likely to fail corticosteroids (>45 points), and at day 5 to dictate the introduction of second-line therapy (>65–70 points). Cyclosporine is successful in children with severe colitis but its use should be restricted to 3–4 months while bridging to thiopurine treatment (pooled short-term success rate 81% [95% CI: 76%–86%]; n = 94 from eight studies). Infliximab may be as effective as cyclosporine (75% pooled short-term response (95% CI: 67%–83%); n = 126, six studies) with a pooled 1-year response of 64% (95% CI: 56%–72%). In toxic megacolon, in patients refractory to one salvage medical therapy, and in chronic severe disease, colectomy may be preferred. Decision-making regarding colectomy in children must consider the toxicity of medication consumed over many future years, the quality of life and self-image associated with either choice, as well as both functional outcomes and, in females, fertility following pouch procedures. (Inflamm Bowel Dis 2011;)